Megan achieved her first-class BSc in Biology and distinction in her MSc in Cancer Cell Biology from the University of Sussex. At university she worked in an academic lab and completed literature research focusing on microbiology and genetics, as well as cancer development and therapeutics. She joined Beacon Targeted Therapies in 2022 as the lead researcher on both the Cancer Vaccine and Oncolytic Viruses modules, where she creates newsletters, monthly digests, reports, and presents at global life sciences conferences.